ArticleWorld journal of surgical oncology2020
Treatment patterns and survival outcomes of advanced hypopharyngeal squamous cell carcinoma.
Article in World journal of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Upfront Surgery Versus Upfront Concurrent Chemoradiotherapy as Primary Modality in Hypopharyngeal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-facialePooled it
- Induction toripalimab plus chemotherapy sequential concurrent chemoradiotherapy with nimotuzumab followed by toripalimab maintenance in stage IVB hypopharyngeal squamous cell carcinoma: a single-arm phase 2 study.Journal for immunotherapy of cancer · 2026Trial
- Development and validation of a nomogram to predict cancer-specific survival in patients with hypopharyngeal squamous cell carcinoma treated with primary surgery.The Journal of international medical research · 2021Trial
- A Web-Based Prediction Model for Cancer-Specific Survival of Elderly Patients With Hypopharyngeal Squamous Cell Carcinomas: A Population-Based Study.Frontiers in public health · 2021Trial
- Does Omitting Distal Anastomosis in Hypopharyngeal Defect Reconstruction Improve Dietary Outcomes?The Laryngoscope · 2026Article
- Risk factors for second primary esophageal cancer after head and neck squamous cell carcinoma: a systematic review and meta-analysis.ESMO gastrointestinal oncology · 2026Review
- USP7-stabilized CEBPB promotes HpSCC progression by upregulating IL6 to activate the JAK2/STAT3 signaling.Molecular and cellular biochemistry · 2026Article
- Circumferential laryngopharyngectomy with free jejunal transfer for hypopharyngeal cancer: a retrospective cohort analysis of outcomes and complications.Frontiers in surgery · 2026Article
- Prognostic Factors in Patients With Locally Advanced Hypopharyngeal Squamous Cell Carcinoma After Radical Radiotherapy/Chemoradiotherapy.Cancer medicine · 2025Article
- Prognostic Factors and Long-Term Outcome Prediction in Patients with Hypopharyngeal Carcinoma Treated with (Chemo)radiotherapy: Development of a Prognostic Model.Biomedicines · 2025Article
- Case Report: Photodynamic therapy meets Chinese herbal medicine: a promising approach for advanced hypopharyngeal carcinoma.Frontiers in pharmacology · 2025Article
- Patterns of recurrence in HNSCC patients treated definitively with upfront surgery, chemoradiation.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024Article
- Article
- Nomogram-derived immune-inflammation-nutrition score could act as a novel prognostic indicator for patients with head and neck squamous cell carcinoma.Frontiers in immunology · 2024Article
- Article
- Developing a predictive nomogram and web-based survival calculator for locally advanced hypopharyngeal cancer: A propensity score-adjusted, population-based study.Biomolecules & biomedicine · 2023Article
- Application value of whole exome sequencing in screening and identifying novel mutations of hypopharyngeal cancer.Scientific reports · 2023Article
- Survival analyses of different treatment modalities and clinical stage for hypopharyngeal carcinoma.Frontiers in oncology · 2023Article
- Quantitative parameters derived fromNeuroradiology · 2022Article
- Robotic surgery may improve overall survival for T1 and T2 tumors of the hypopharynx: An NCDB cohort study.Oral oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundThis study evaluated the treatment outcomes of the primary surgery (PS) or concurrent chemoradiotherapy (CCRT) as the initial treatment for hypopharyngeal squamous cell carcinoma (HPSCC).
methodsThis retrospective cohort study included patients with stages III-IV HPSCC from four tertiary referral centers consecutively enrolled from 2003 to 2012; of them, 213 (32.6%) and 439 (67.4%) had received PS and CCRT as their primary treatments, respectively. The 5-year overall survival (OS) and disease-free survival (DFS) rates were analyzed using the Kaplan-Meier method and Cox regression models.
resultsIn patients undergoing PS and CCRT, OS rates were 45.0% and 33.1% (p < 0.001), respectively, and DFS rates were 36.2% and 28.9% (p = 0.003), respectively. In subgroup analysis, in patients with stage IVA HPSCC, PS was associated with higher OS rate (p = 0.002), particularly in those with T4 or N2 classification (p = 0.021 and 0.002, respectively). Multivariate analysis indicated that stage IVA HPSCC, stage IVB HPSCC, and CCRT were independent adverse prognostic factors for OS rate (p = 0.004, < 0.001, and 0.014, respectively). Furthermore, in patients with stage IVA HPSCC aged ≥ 65 years and with N2 classification, CCRT was significantly associated with lower OS rates than was PS (p = 0.027 and 0.010, respectively).
conclusionsIn patients with advanced HPSCC, PS was significantly associated with better prognosis than CCRT. PS could be a favorable primary treatment modality for the management of patients with stage IVA HPSCC, particularly those aged ≥ 65 years and with T4 and N2 classification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.